TrialBMC cancer2021

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.

Wei Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.